abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

LY6G6D
Back
Total number of drugs
2
Phase II and later clinical stages
0%
Involving companies
2
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
Anti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma)Anti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma)NanobodyNeoplasms Digestive System Disorderslymphocyte antigen 6 family member G6D inhibitorsShanghai Hongcheng Pharmaceutical Co. Ltd.Shanghai Hongcheng Pharmaceutical Co. Ltd.PreclinicalPreclinicalAnti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma)
detail  >
IMD-2206IMD-2206Antibody drug conjugate (ADC) ADCNeoplasmslymphocyte antigen 6 family member G6D inhibitorsShanghai Affinity Biopharmaceutical Co., Ltd.PreclinicalPreclinicalIMD-2206
detail  >
Total 2 data
1